Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/ccd.29718 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Making Sense of John Harris and : An Enigma, Wrapped in Mysterious Contradictions, inside an Absence of Theoretical Commitments?
Camb Q Healthc Ethics
January 2025
Centre for Health, Law, and Society, University of Bristol Law School, Bristol, UK.
This paper critically engages with the work of John Harris. Its central focus is his 1985 book, : a foundational text in philosophical bioethics, whose relevance and resonance continue firmly to endure. My aim is to examine what it says-and omits to say-about political authority.
View Article and Find Full Text PDFReichert's membrane - A continuing enigma for developmental biologists.
Dev Biol
January 2025
Developmental Biology & Cancer Department, UCL Great Ormond Street Institute of Child Health, London, UK. Electronic address:
Reichert's membrane (RM) is a basement membrane of gigantic proportions that surrounds the mammalian embryo following implantation. It is part of the parietal yolk sac, which originates from the wall of the preimplantation blastocyst. RM persists from implantation to birth in rodents and analogous structures occur in other mammals, including primates.
View Article and Find Full Text PDFLFA-1: A potential key player in microglia-mediated neuroprotection against oxygen-glucose deprivation in vitro.
PLoS One
January 2025
Medical Faculty, Department of Neurology, Otto von Guericke University, Magdeburg, Germany.
For the last 38 years, all neuroprotective agents for patients with ischemic stroke have failed in clinical trials. The innate immune system, particularly microglia, is a much-discussed target for neuroprotective agents. Promising results for neuroprotection by inhibition of integrins with drugs such as natalizumab in animal stroke models have not been translated into clinical practice.
View Article and Find Full Text PDFA case report about focal status epilepticus as first presentation in Alzheimer's disease: finding the culprit.
BMC Neurol
December 2024
Laboratory for Epilepsy Research, KU Leuven, Belgium.
Background: Neuronal hyperexcitability has been proposed to play a key role in Alzheimer's disease (AD). Understanding the relation between this enhanced excitability and AD pathology could provide a window for therapeutic interventions. However epileptiform activity is often subclinical, hidden on scalp EEG and very challenging to assess with current diagnostic modalities.
View Article and Find Full Text PDFA phase 4, multicenter, global clinical study to evaluate discontinuation and rechallenge of pexidartinib in patients with tenosynovial giant cell tumor previously treated with pexidartinib.
Cancer
January 2025
Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Article Synopsis
- Pexidartinib is a drug used for treating tenosynovial giant cell tumor (TGCT) in patients where surgery isn't an option, and this study looked at the effects of stopping and then restarting the medication.
- It was a phase 4 global study involving patients who had benefited from pexidartinib, allowing them to either continue treatment or stop with the option to restart later, monitoring their tumor progression and quality of life.
- Results showed that while about 54.5% of patients who stopped the drug experienced disease progression, none of those who continued treatment saw their condition worsen over a 24-month period.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!